146 related articles for article (PubMed ID: 9465588)
1. Effects of bromocriptine and terguride on cell proliferation and apoptosis in the estrogen-stimulated anterior pituitary gland of the rat.
Yonezawa K; Tamaki N; Kokunai T
Neurol Med Chir (Tokyo); 1997 Dec; 37(12):901-6. PubMed ID: 9465588
[TBL] [Abstract][Full Text] [Related]
2. Terguride as a new anti-hyperprolactinemic agent: characterization in rats and dogs in comparison with bromocriptine.
Mizokawa T; Akai T; Nakada Y; Yamaguchi M; Nakagawa H; Hasan S; Rettig KJ; Wachtel H
Jpn J Pharmacol; 1993 Nov; 63(3):269-78. PubMed ID: 7906316
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and medical treatment of male prolactinomas.
Asano S; Ueki K; Suzuki I; Kirino T
Acta Neurochir (Wien); 2001; 143(5):465-70. PubMed ID: 11482696
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects.
Gruszka A; Pawlikowski M; Kunert-Radek J
Neuro Endocrinol Lett; 2001 Oct; 22(5):343-8. PubMed ID: 11600876
[TBL] [Abstract][Full Text] [Related]
5. [Results of treatment for male prolactinomas].
Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional imaging of hormone-secreting cells and their microvessel environment in estrogen-induced prolactinoma of the rat pituitary gland by confocal laser scanning microscopy.
Itoh J; Kawai K; Serizawa A; Yamamoto Y; Ogawa K; Matsuno A; Watanabe K; Osamura RY
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):364-70. PubMed ID: 11759065
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
8. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
Stepień H; Lawnicka H; Mucha S; Wagrowska-Danilewicz M; Stepień B; Siejka A; Komorowski J
Life Sci; 2006 Sep; 79(18):1741-8. PubMed ID: 16846617
[TBL] [Abstract][Full Text] [Related]
10. Independence of estrogen-induced pituitary proliferation on local IGF-I mRNA and EGF mRNA expression. Modifying effects of tamoxifen and terguride.
Hána V; Haluzík M; Schreiber V
Physiol Res; 1998; 47(2):125-31. PubMed ID: 9706996
[TBL] [Abstract][Full Text] [Related]
11. Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine.
Ciccarelli E; Touzel R; Besser M; Grossman A
Fertil Steril; 1988 Apr; 49(4):589-94. PubMed ID: 3127243
[TBL] [Abstract][Full Text] [Related]
12. Effects of bromocriptine on staining indices of Ki-67 and proliferating cell nuclear antigen, and nucleolar organizer region number in pituitary adenomas.
Ekramullah SM; Saitoh Y; Ohnishi T; Arita N; Taki T; Hayakawa T
Neurol Med Chir (Tokyo); 1995 Apr; 35(4):221-6. PubMed ID: 7596464
[TBL] [Abstract][Full Text] [Related]
13. [Prolactinoma in man: clinical and histological characteristics].
Trouillas J; Delgrange E; Jouanneau E; Maiter D; Guigard MP; Donckier J; Perrin G; Jan M; Tourniaire J
Ann Endocrinol (Paris); 2000 Sep; 61(3):253-7. PubMed ID: 10970951
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
[TBL] [Abstract][Full Text] [Related]
15. The long-term effects of pregnancy and bromocriptine treatment on prolactinomas--the value of radiologic studies.
Badawy SZ; Marziale JC; Rosenbaum AE; Chang JK; Joy SE
Early Pregnancy; 1997 Dec; 3(4):306-11. PubMed ID: 10086082
[TBL] [Abstract][Full Text] [Related]
16. Giant prolactinoma: where's the prolactin?
Tailor C; Teo I; Sorisky A
Clin Neurol Neurosurg; 2011 Nov; 113(9):810-2. PubMed ID: 21906866
[No Abstract] [Full Text] [Related]
17. Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas.
Bai J; Gui S; Zhang Y
J Clin Neurosci; 2013 May; 20(5):721-5. PubMed ID: 23523357
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic resistance in prolactinoma patients.
Molitch ME
Pituitary; 2005; 8(1):43-52. PubMed ID: 16411068
[TBL] [Abstract][Full Text] [Related]
19. Effects of tamoxifen on serum prolactin levels, pituitary immunoreactive prolactin cells and uterine growth in estradiol-treated ovariectomized rats.
Spritzer PM; Ribeiro MF; Oliveira MC; Barbosa-Coutinho LM; Silva IS; Dahlem N; Cericatto R; Pavanato MA
Horm Metab Res; 1996 Apr; 28(4):171-6. PubMed ID: 8740191
[TBL] [Abstract][Full Text] [Related]
20. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly.
Dallabonzana D; Liuzzi A; Oppizzi G; Verde G; Chiodini PG; Dorow R; Horowski R
J Endocrinol Invest; 1985 Apr; 8(2):147-51. PubMed ID: 4031381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
